GUARDANT HEALTH, INC.
At today's price, GUARDANT HEALTH, INC. (GH) is priced for today's economics sustained for ~20.8 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
Guardant does not yet earn an operating profit, so the market prices it on sales: about 18 times revenue. That multiple implies the business eventually reaches a roughly 26% operating margin and grows revenue near its self-funding ceiling for close to 19 years. The business is scaling fast. Q1 2026 revenue rose 48% to $301.7 million, and the Shield colorectal screening line jumped from $5.7 million to $41.6 million as test volume and reimbursement improved. The growth is real; the question is t
Is GH overvalued? See what's priced in →
469 institutional managers reported holding GH in 13F filings for the quarter ended 2026-03-31. 60 opened new positions that quarter. Held by Vanguard Group, BlackRock, T. Rowe Price, among others. On the short side, 13.1M shares were sold short as of the 2026-06-15 count, about 10% of shares outstanding (6.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
GH's share count grew 29.8% over the past five years even with $45.01M spent on repurchases. It pays no dividend. Cash returned over the past three years: $45.01M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at GH over the trailing three years: 2024: 1 buy totaling $39k; 2026: 1 buy totaling $78k. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
GH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | +17.2% | +37.0% |
| 2023-08-04 | +4.7% | -24.7% |
| 2023-11-07 | -8.5% | -0.8% |
| 2024-02-23 | -14.3% | -10.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
GH's latest 8-K filings: 2026-06-18 (items 5.07); 2026-05-07 (items 2.02, 9.01); 2026-04-27 (items 5.02); 2026-02-19 (items 2.02, 9.01); 2026-01-12 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.